Pituitary tumor
diseaseOn this page
Also known as neoplasm of pituitaryneoplasm of pituitary glandneoplasm of the pituitaryneoplasm of the pituitary glandpituitary gland neoplasmpituitary gland tumorpituitary gland tumourpituitary neoplasmtumor of pituitarytumor of pituitary glandtumor of the pituitarytumor of the pituitary glandtumour of pituitarytumour of pituitary glandtumour of the pituitarytumour of the pituitary gland
Summary
Pituitary tumor (MONDO:0017611) is a cancer (an umbrella term covering 9 Mondo subtypes) and 75 clinical trials. Top therapeutic interventions include cabergoline, bromocriptine, and corticorelin ovine triflutate. A subtype of endocrine gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 9 Mondo subtypes
- Clinical trials: 75
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pituitary tumor |
| Mondo ID | MONDO:0017611 |
| Orphanet | 304055 |
| NCIT | C3330 |
| SNOMED CT | 127024001 |
| UMLS | C0032019 |
| MedGen | 19326 |
| GARD | 0021253 |
| Anatomy (UBERON) | UBERON:0000007 |
| Is cancer (heuristic) | yes |
Also known as: neoplasm of pituitary · neoplasm of pituitary gland · neoplasm of the pituitary · neoplasm of the pituitary gland · pituitary gland neoplasm · pituitary gland tumor · pituitary gland tumour · pituitary neoplasm · pituitary tumor · tumor of pituitary · tumor of pituitary gland · tumor of the pituitary · tumor of the pituitary gland · tumour of pituitary · tumour of pituitary gland · tumour of the pituitary · tumour of the pituitary gland
Disease family
This is a subtype of endocrine gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › pituitary tumor
Related subtypes (13): benign endocrine neoplasm, thymus neoplasm, granulosa cell tumor, thyroid tumor, familial tumoral calcinosis, neuroendocrine neoplasm, malignant endocrine neoplasm, non-functioning endocrine neoplasm, functioning endocrine neoplasm, adrenal gland neoplasm, pineal body neoplasm, tumor of parathyroid gland, liver and intrahepatic bile duct neoplasm
Subtypes (9): pituitary cancer, posterior pituitary gland neoplasm, prolactin producing pituitary tumor, non-functioning pituitary gland neoplasm, functioning pituitary gland neoplasm, pituitary gland adenoma, growth hormone-producing pituitary gland neoplasm, benign neoplasm of pituitary gland, ACTH-producing pituitary gland neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 75.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 57 |
| PHASE2 | 7 |
| PHASE4 | 5 |
| PHASE1 | 3 |
| EARLY_PHASE1 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01794793 | PHASE4 | COMPLETED | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies |
| NCT02190994 | PHASE4 | UNKNOWN | Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions |
| NCT02351700 | PHASE4 | COMPLETED | Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors |
| NCT02549768 | PHASE4 | UNKNOWN | Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery |
| NCT03132259 | PHASE4 | UNKNOWN | Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach |
| NCT02288962 | PHASE3 | ACTIVE_NOT_RECRUITING | Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas |
| NCT04042753 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors |
| NCT00001860 | PHASE2 | COMPLETED | Sandostatin LAR Depot vs. Surgery for Treating Acromegaly |
| NCT00003514 | PHASE2 | WITHDRAWN | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy |
| NCT00958841 | PHASE2 | TERMINATED | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin |
| NCT01689727 | PHASE2 | COMPLETED | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors |
| NCT02749227 | PHASE2 | TERMINATED | Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors |
| NCT04863339 | PHASE2 | WITHDRAWN | Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
| NCT02629549 | PHASE1 | TERMINATED | Intraoperative Imaging of Pituitary Adenomas by OTL |
| NCT04212793 | PHASE1 | COMPLETED | Detection of PitNET Tissue During TSS Using Bevacizumab-800CW |
| NCT07254104 | EARLY_PHASE1 | ENROLLING_BY_INVITATION | Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors |
| NCT01459237 | EARLY_PHASE1 | COMPLETED | Effects of Hormone Stimulation on Brain Scans for Cushing s Disease |
| NCT00599092 | Not specified | RECRUITING | Pituitary Tumor Surveillance: Pathogenic Correlation |
| NCT03665064 | Not specified | ACTIVE_NOT_RECRUITING | Long Term Outcome Study in Patients With Pituitary Disorders |
| NCT03678389 | Not specified | RECRUITING | Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery |
| NCT04087902 | Not specified | ACTIVE_NOT_RECRUITING | Long-Term Longitudinal QoL in Patients Undergoing EEA |
| NCT05139277 | Not specified | RECRUITING | Evaluation of the CONVIVO System |
| NCT05659524 | Not specified | RECRUITING | Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery |
| NCT06266949 | Not specified | NOT_YET_RECRUITING | Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors |
| NCT06282224 | Not specified | RECRUITING | Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery |
| NCT06472505 | Not specified | RECRUITING | Using Polyglycolic Acid Mesh Prevents Cerebrospinal Fluid Leakage |
| NCT06523582 | Not specified | RECRUITING | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients |
| NCT06556186 | Not specified | NOT_YET_RECRUITING | Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma |
| NCT06705036 | Not specified | RECRUITING | Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions |
| NCT06936813 | Not specified | ACTIVE_NOT_RECRUITING | The PROMISE Survey |
| NCT07594262 | Not specified | RECRUITING | NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm |
| NCT00001171 | Not specified | COMPLETED | Evaluation of Factors in Human Brain Tumors |
| NCT00001981 | Not specified | COMPLETED | The Treatment and Natural History of Acromegaly |
| NCT00005664 | Not specified | TERMINATED | Evaluation of Patients With Endocrine-Related Conditions |
| NCT00462475 | Not specified | COMPLETED | Effect of 5 Years of GH Replacement on Atherosclerosis |
| NCT00565903 | Not specified | COMPLETED | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome |
| NCT00598949 | Not specified | UNKNOWN | Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma |
| NCT00646308 | Not specified | TERMINATED | Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas |
| NCT00852501 | Not specified | UNKNOWN | Characterization of Receptors in Non-functioning Pituitary Macroadenomas |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABERGOLINE | 4 | 3 |
| BROMOCRIPTINE | 4 | 1 |
| CORTICORELIN OVINE TRIFLUTATE | 4 | 1 |
| HYDROCORTISONE | 4 | 1 |
| PAFOLACIANINE | 4 | 1 |
| PASIREOTIDE | 4 | 1 |
| PREDNISONE | 4 | 1 |
| ANTINEOPLASTON A10 | 3 | 1 |
| CHEMBL4593105 | 0 | 3 |
| CHEMBL5192470 | 0 | 3 |
| CHEMBL15720 | 0 | 1 |